February 26, 2015

The New Humphrey Field Analyzer 3 from ZEISS Sets a New Standard for Efficient Visual Field Testing

New HFA3 offers gold-standard perimetry performance with technological advances – such as automated trial lens correction – that are designed to save time and reduce errors, plus test results equal to and interchangeable with test results from previous Humphrey perimeters.

DUBLIN, California/USA, Coronado, California/USA

For more than 30 years, the Humphrey® Field Analyzer (HFA™) has been the accepted standard of care in glaucoma diagnostics and management. At the American Glaucoma Society 2015 Annual Meeting in Coronado, California, ZEISS is announcing the worldwide launch of the HFA3, the next generation in visual field testing and analysis. The HFA3 is designed to accelerate clinic flow while delivering the same gold-standard testing strategies and test patterns.

The HFA3 upholds the Humphrey tradition of accuracy: test results on the new platform are equal to and interchangeable with results from prior generations of the HFA, providing continuity and certainty in the ongoing care of patients.

The HFA3 is the first perimeter to introduce patented Liquid Lens technology, which saves time, simplifies set-up and reduces the possibility of human error in trial lens correction. In perimetry, a trial lens provides the refractive correction needed so each patient can see clearly during the test. The HFA3 replaces the old manual process with a patented Liquid Trial Lens™, which automatically delivers the appropriate refractive correction using measurement information entered into the instrument.

The HFA3 provides a streamlined and faster workflow with an array of new features designed to:

  • Improve confidence in test results with RelEYE™, which allows doctors to instantly review the patient’s eye position, at any stimulus point. RelEYE data is available on the instrument and when reviewing test results with FORUM® Glaucoma Workplace. It may reveal common testing problems, such as droopy lids (ptosis) or misalignment of the eye relative to the trial lens holder. 
  • Save time with an intuitive new SmartTouch™ interface, which reduces the number of steps required for the technician to start a perimetry exam. Faster gaze tracking provides information that helps doctors assess the reliability of test results. The gaze tracker on the HFA3 provides faster initialization and works on a wider spectrum of patients, compared to earlier models of HFA. 
  • Make test administration simpler, with an easy-to-use kinetic graphical user interface with a full 180-degree field of view.

“The HFA3, together with the other components of the ZEISS glaucoma management offerings, delivers an unrivaled combination of seamless integration and diagnostic performance to eye professionals who diagnose and manage glaucoma,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Press contact

Bill Taggart, Group Communications, Carl Zeiss Meditec, Inc.
Dublin, California
Mobile +1 925-493-9251
Email: william .taggart @zeiss .com

Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone +49 (0) 3641 220-331
Email: press .meditec @zeiss .com

Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0) 3641 220-116,
Email: investors .meditec @zeiss .com


www.meditec.zeiss.com/press

WEB.5388